Document Detail


Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
MedLine Citation:
PMID:  21029824     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The objective of the present study was to assess the safety and effectiveness of vernakalant hydrochloride injection (RSD1235), a novel antiarrhythmic drug, for the conversion of atrial fibrillation (AF) or atrial flutter to sinus rhythm (SR). Patients with either AF or atrial flutter were randomized in a 1:1 ratio to receive vernakalant (n = 138) or placebo (n = 138) and were stratified by an arrhythmia duration of >3 hours to ≤7 days (short duration) and 8 to ≤45 days (long duration). The first infusion of placebo or vernakalant (3 mg/kg) was given for 10 minutes followed by a second infusion of placebo or vernakalant (2 mg/kg) 15 minutes later if the arrhythmia had not terminated. A total of 265 patients were randomized and received treatment. The primary end point was conversion of AF to SR for ≥1 minute within 90 minutes of the start of the drug infusion in the short-duration AF group. Of the 86 patients receiving vernakalant in the short-duration AF group, 44 (51.2%) demonstrated conversion to SR compared to 3 (3.6%) of the 84 in the placebo group (p <0.0001). The median interval to conversion of short-duration AF to SR in the responders given vernakalant was 8 minutes. Of the entire AF population (short- and long-duration AF), 47 (39.8%) of the 118 vernakalant patients experienced conversion of AF to SR compared to 4 (3.3%) of the 121 placebo patients (p <0.0001). Transient dysgeusia and sneezing were the most common adverse events in the vernakalant patients. One vernakalant patient who had severe aortic stenosis experienced hypotension and ventricular fibrillation and died. In conclusion, vernakalant demonstrated a rapid and high rate of conversion for short-duration AF and was well tolerated.
Authors:
Craig M Pratt; Denis Roy; Christian Torp-Pedersen; D George Wyse; Egon Toft; Steen Juul-Moller; Enrique Retyk; David Humphrey Drenning;
Related Documents :
19207134 - Magnesium sulfate versus placebo for paroxysmal atrial fibrillation: a randomized clini...
12930494 - Clinical predictors and time course of arrhythmia recurrence in patients with early rei...
19379884 - Intermediate-term outcomes of surgical atrial fibrillation correction with the cryomaze...
19187904 - Temporal left atrial lesion formation after ablation of atrial fibrillation.
17913564 - Shoulder kinematic features using arm elevation and rotation tests for classifying pati...
7889014 - Pulmonary function and complications subsequent to autologous bone marrow transplantation.
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of cardiology     Volume:  106     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-29     Completed Date:  2010-12-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1277-83     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2010 Elsevier Inc. All rights reserved.
Affiliation:
Department of Cardiology, Methodist DeBakey Heart and Vascular Center, Methodist Research Institute, Houston, Texas, USA. cpratt@tmhs.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anisoles / administration & dosage,  adverse effects,  therapeutic use*
Anti-Arrhythmia Agents / administration & dosage,  adverse effects,  therapeutic use*
Atrial Fibrillation / drug therapy*,  physiopathology
Atrial Flutter / drug therapy,  physiopathology
Chi-Square Distribution
Double-Blind Method
Female
Humans
Infusions, Intravenous
Male
Middle Aged
Placebos
Prospective Studies
Pyrrolidines / administration & dosage,  adverse effects,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anisoles; 0/Anti-Arrhythmia Agents; 0/Placebos; 0/Pyrrolidines; 0/vernakalant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Relation between obesity and the attainment of optimal blood pressure and lipid targets in high vasc...
Next Document:  Meta-analysis of the effectiveness and safety of catheter ablation of atrial fibrillation in patient...